Sorafenib tosylate
|
|
|
- CAS-Nr.
- 475207-59-1
- Englisch Name:
- Sorafenib tosylate
- Synonyma:
- CL050;Sorafenib &Sorafeni tosylate;Sorafinib mesylate;SORAFENIB TOSYLATE;Sorafenib (Nexavar);Sorafenib TsOH salt;Sorafenib 475207-59-1;Sorafenib tosylate API;BAY 43-9006;BAY43-9006
- CBNumber:
- CB92131200
- Summenformel:
- C21H16ClF3N4O3.C7H8O3S
- Molgewicht:
- 637.03
- MOL-Datei:
- 475207-59-1.mol
|
Sorafenib tosylate Eigenschaften
- Schmelzpunkt:
- 229-232°C
- storage temp.
- 2-8°C(protect from light)
- L?slichkeit
- Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 3 mg/ml).
- Aggregatzustand
- solid
- Farbe
- Off-white
- Stabilit?t:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.
- InChIKey
- IVDHYUQIDRJSTI-UHFFFAOYSA-N
- SMILES
- S(C1C=CC(C)=CC=1)(O)(=O)=O.O(C1C=CC(NC(=O)NC2C=CC(Cl)=C(C(F)(F)F)C=2)=CC=1)C1=CC=NC(C(=O)NC)=C1
- CAS Datenbank
- 475207-59-1(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H362 |
Kann S?uglinge über die Muttermilch sch?digen. |
Reproductive toxicity, effects on or via lactation |
Additional category |
|
|
P201, P260, P263, P264, P270,P308+P313 |
| H372 |
Sch?digt bei Hautkontakt und Verschlucken die Organe bei l?ngerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) |
Kategorie 1 |
Achtung |
![GHS hazard pictograms]() src="/GHS08.jpg" width="20" height="20" /> |
P260, P264, P270, P314, P501 |
| H410 |
Sehr giftig für Wasserorganismen mit langfristiger Wirkung. |
Langfristig (chronisch) gew?ssergef?hrdend |
Kategorie 1 |
Warnung |
![GHS hazard pictograms]() src="/GHS09.jpg" width="20" height="20" /> |
P273, P391, P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P263 |
Kontakt w?hrend der Schwangerschaft /und der Stillzeit vermeiden. |
| P273 |
Freisetzung in die Umwelt vermeiden. |
| P308+P313 |
BEI Exposition oder falls betroffen: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
|
Sorafenib tosylate Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.
Trademarks
Nexavar (Bayer).
Allgemeine Beschreibung
Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and colon cancer.The agent is classified as a multikinase inhibitor because ofits action on numerous kinase enzymes including thePDGF-R, VEGF-R, Kit, and Raf. Sorafenib is 39% to 48% bioavailable and CYP3A4-mediated metabolism giveseight identified metabolites including the N-oxide, which isequally active with the parent. However, the majority of thedrug in plasma is present as the parent compound.Sorafenib is highly protein bound (99.5%). The drug iseliminated primarily in the feces (77%) with 19% appearingin the urine as glucuronides (UGT1A1) and has a eliminationhalf-life of 24 to 48 hours. The most commonly seentoxicity is skin rash that normally occurs within the first6 weeks of therapy. Other adverse effects include hypertension,fatigue, increased wound healing time, and increasedrisk of bleeding.
Nebenwirkungen
The side effects of Sorafenib tosylate include Bleeding gums, blistering, peeling, redness, or swelling of the palms of the hands or bottoms of the feet, bloating of the abdomen or stomach,
blood in the urine or stools, clay-colored stools,
coughing up blood, difficulty with breathing or swallowing, increased menstrual flow or vaginal bleeding.
Sorafenib tosylate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Sorafenib tosylate Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 581)Lieferanten
475207-59-1()Verwandte Suche:
- SORAFENIB TOSYLATE
- Sorafenib & its intermediates
- Sorafinib mesylate
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate
- Sorafenib Tosylate(Bay 43-9006,Nexavar)
- 2-PyridinecarboxaMide, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-N-Methyl-, 4-Methylbenzenesulfonate
- Sorafenib Tosylate (Nexavar)
- Sorafenib (Nexavar)
- Sorafenib tosylate API
- 1-(4-Chloro-3-(trifluoroMethyl)phenyl)-3-(4-((2- (MethylcarbaMoyl)pyridin-4-yl)oxy)phenyl)urea Mono(4- Methylbenzenesulfonate)
- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1)
- Sorafenib TsOH salt
- Sorafenib, p-Toluenesulfonate Salt, >99%
- Sorafenib &
- Sorafenib tosylate, >=99%
- 4-[4-[[[[4-chloro-3-((trifluoromethyl))phenyl]amino]carbonyl]amino]phenoxy]-N-methylpyridin-2-carboxamide tosylate (1:1)
- 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrim
- Sorafeni tosylate
- SORAFENIB TOSYLATE (BAY 43-9006 TOSYLATE)
- BAY 43-9006;BAY43-9006
- 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N2-methylpyridine-2-carboxamide mono (4-methylbenzenesulfonate)
- Sorafenib (BAY-43-9006)
- Sorafenib 475207-59-1
- Sorafenib tosylate-002
- Sorafenib tosylate(Nexavar，SORENIC)
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate Sorafenib Tolsylate
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate
- CL050
- Sorafenib degradation (Sorafenib)
- 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-2-pyridinecarboxamide Tosylate
- 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N2-methylpyridine-2-carboxamide mono (4-methylbenzenesulfonate)c
- Sorafenib tosylate USP/EP/BP
- Sorafenib Tosylate (MFDS)
- Bay 43-9006 (Tosylate)
- Sorafenib Tosylate (Bay 43-9006
- Sorafenib tosylateQ: What is
Sorafenib tosylate Q: What is the CAS Number of
Sorafenib tosylate Q: What is the storage condition of
Sorafenib tosylate Q: What are the applications of
Sorafenib tosylate
- Sorafenib toluene sulfonate
- 1,8-Butanediol,monomethanesulfonate
- 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide 4-methylbenzenesulfonate
- Toluenesulfonic acid sorafenib
- Sorafenib (BAY 43-9006) tosylate
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate Sorafenib Tolsylate
- Pinacolborane Impurity 11
- Sorafenib tosylate, 10 mM in DMSO
- 475207-59-1
- C21H16ClF3N4O3C7H8SO
- C21H16ClF3N4O3C7H8O3S
- C29H26F3N7O4S
- C28H24ClF3N4O6S
- Bay 43-9006
- Inhibitors
- MAPK
- API
